Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

被引：0

作者：

Wolf Köster

G. Stamatis

A. Heider

K. Avramidis

H. Wilke

J.A. Koch

M. Stahl

机构：

[1] Klinik für Innere Medizin I und IV,Kliniken Essen

[2] Internistische Onkologie/Hämatologie,Mitte, Evangelische Huyssens

[3] Zentrum für Palliativmedizin,Stiftung

[4] Ruhrlandklinik Essen,undefined

[5] Klinikum Leverkusen,undefined

来源：

Clinical Drug Investigation | 2004年 / 24卷

关键词：

Dose Level; Carboplatin; Small Cell Lung Cancer; Maximum Tolerate Dose; Haematological Toxicity;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background and objective: Bendamustine is an alkylating agent with high efficacy in non-Hodgkin’s lymphoma and multiple myeloma. Even in solid tumours, monotherapy with bendamustine has resulted in subjective remissions and has been associated with a low rate of side effects. The current dose-finding study was designed to determine the maximum tolerated dose (MTD) of combined carboplatin/bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC).

引用

页码：611 / 618

页数：7

共 50 条

[1] Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC)
Köster, W
Stamatis, G
Heider, A
Avramidis, K
Wilke, H
Koch, JA
Stahl, M
[J]. CLINICAL DRUG INVESTIGATION, 2004, 24 (10) : 611 - 618
[2] A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)
Chiappori, A.
Schreeder, M. T.
Moezi, M. M.
Stephenson, J.
Blakely, J. L.
Salgia, R.
Chu, Q. S.
Malik, S. M.
Modiano, M. M.
Berger, M. S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[3] Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a metaanalysis
Xu, Fei
Ren, Xiaoli
Chen, Yuan
Li, Qianxia
Li, Ruichao
Chen, Yu
Xia, Shu
[J]. BMC CANCER, 2018, 18
[4] Carboplatin (C) and etoposide (E) in previously untreated extensive stage small cell lung cancer (ED-SCLC)
Yilmaz, U.
Halilcolar, H.
Yildirim, Y.
Yapicioglu, S.
Unsal, I.
Kuzer, P.
Altiparmak, O.
Cinar, T.
[J]. LUNG CANCER, 2006, 52 : S43 - S43
[5] Irinotecan, carboplatin, and bevacizumab in untreated extensive-stage small-cell lung cancer
Spigel, David R.
Hainsworth, John D.
Burris, Howard A.
Yardley, Denise A.
Farley, Cindy
Meng, Christina
Greco, Anthony F.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S391 - S391
[6] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB IN COMBINATION WITH CARBOPLATIN AND ETOPOSIDE IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Pinheiro, B.
Cardoso, M.
Lourenco, F.
Orfanos, P.
Castro, A. Y.
Celik, H.
Belleli, R.
Borges, M.
Silva Miguel, L.
[J]. VALUE IN HEALTH, 2020, 23 : S437 - S438
[7] Prognostic Factors in Extensive-Stage Small Cell Lung Cancer (SCLC)
De Almeida, S. B.
Vitorino, M.
Goncalves, S.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S34 - S35
[8] A phase I and Pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer
Lee, Dae Ho
Kim, Sang-We
Bae, Kyun-Seop
Hong, Jeong-Sook
Suh, Cheolwon
Kang, Ybon-Koo
Lee, Jung-Shin
[J]. CLINICAL CANCER RESEARCH, 2007, 13 (20) : 6182 - 6186
[9] Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
Fei Xu
Xiaoli Ren
Yuan Chen
Qianxia Li
Ruichao Li
Yu Chen
Shu Xia
[J]. BMC Cancer, 18
[10] A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer
Lee, J.
Lee, D.
Bae, K.
Kim, S.
Suh, C.
Shin, J.
Hong, J.
Kang, Y.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →